Skip to content

Study · Animal study (in vivo) · mouse · 2024

9 results

Intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions improves cognitive impairments in a mouse model of Alzheimer's disease.

Zuglianello C, França AP, de Souza BS, Agnes JP, Prediger RD, Lemos-Senna E

International journal of biological macromolecules1 Oct 2024Cited by 2 (Europe PMC)

PMID39362444 (opens in a new tab)DOI10.1016/j.ijbiomac.2024.136158 (opens in a new tab)PepBankPUB-39362444
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, pramlintide treatment did not affect locomotor activity.

    In plain wordsIn mice, pramlintide did not change movement activity.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeLocomotor activity
    Study

    mousen: not reported in source

    amyloid-beta-induced Alzheimer's disease model
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    100 μg/day · intranasal · 14 consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    The locomotor activity of the animals was not affected by the i.c.v. Aβ1-42 injection or Pram treatment.
    1 context sentence
    Summary · context
    In this study, we examined the effects of the intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions (PEC-NEDexS/Pram) in an experimental model of AD induced by intracerebroventricular (i.c.v.) infusion of amyloid-beta (Aβ1-<sub…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intranasal pramlintide nanoemulsions restored discriminative learning impaired by amyloid-beta injection.

    In plain wordsIn mice, nasal pramlintide nanoemulsions reversed learning impairment caused by amyloid-beta injection.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseDiscriminative learning
    Study

    mousen: not reported in source

    amyloid-beta-induced Alzheimer's disease model
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    100 μg/day · intranasal · 14 consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    On the other hand, the intranasal administration of PEC-NEDexS/Pram at a dose of 100 μg/day for 14 consecutive days restored the impairment induced by Aβ1-42 injection in the discriminative learning and the short-term spatial reference memory of mice.
    1 context sentence
    Summary · context
    In this study, we examined the effects of the intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions (PEC-NEDexS/Pram) in an experimental model of AD induced by intracerebroventricular (i.c.v.) infusion of amyloid-beta (Aβ1-<sub…
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intranasal pramlintide nanoemulsions restored short-term spatial reference memory impaired by amyloid-beta injection.

    In plain wordsIn mice, nasal pramlintide nanoemulsions reversed short-term spatial memory impairment caused by amyloid-beta injection.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseShort-term spatial reference memory
    Study

    mousen: not reported in source

    amyloid-beta-induced Alzheimer's disease model
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    100 μg/day · intranasal · 14 consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    On the other hand, the intranasal administration of PEC-NEDexS/Pram at a dose of 100 μg/day for 14 consecutive days restored the impairment induced by Aβ1-42 injection in the discriminative learning and the short-term spatial reference memory of mice.
    1 context sentence
    Summary · context
    In this study, we examined the effects of the intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions (PEC-NEDexS/Pram) in an experimental model of AD induced by intracerebroventricular (i.c.v.) infusion of amyloid-beta (Aβ1-<sub…
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, pramlintide did not alter amyloid-beta-induced anhedonic behavior.

    In plain wordsIn mice, pramlintide did not change loss of pleasure caused by amyloid-beta.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeAnhedonic behavior
    Study

    mousen: not reported in source

    amyloid-beta-induced Alzheimer's disease model
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    100 μg/day · intranasal · 14 consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    However, Pram treatment did not alter the Aβ1-42-induced anhedonic behavior, oxidative stress parameters, or the pre-synaptic SNAP-25 and post-synaptic PSD-95 levels in the hippocampus and prefrontal cortex.
    1 context sentence
    Summary · context
    In this study, we examined the effects of the intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions (PEC-NEDexS/Pram) in an experimental model of AD induced by intracerebroventricular (i.c.v.) infusion of amyloid-beta (Aβ1-<sub…
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice, pramlintide did not alter amyloid-beta-induced oxidative stress parameters in the hippocampus and prefrontal cortex.

    In plain wordsIn mice, pramlintide did not change brain oxidative stress measures after amyloid-beta exposure.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeOxidative stress parameters
    Study

    mousen: not reported in source

    amyloid-beta-induced Alzheimer's disease model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    100 μg/day · intranasal · 14 consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    However, Pram treatment did not alter the Aβ1-42-induced anhedonic behavior, oxidative stress parameters, or the pre-synaptic SNAP-25 and post-synaptic PSD-95 levels in the hippocampus and prefrontal cortex.
    1 context sentence
    Summary · context
    In this study, we examined the effects of the intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions (PEC-NEDexS/Pram) in an experimental model of AD induced by intracerebroventricular (i.c.v.) infusion of amyloid-beta (Aβ1-<sub…
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice, pramlintide did not alter SNAP-25 levels in the hippocampus and prefrontal cortex after amyloid-beta injection.

    In plain wordsIn mice, pramlintide did not change brain SNAP-25 levels after amyloid-beta injection.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeSNAP-25 levels
    Study

    mousen: not reported in source

    amyloid-beta-induced Alzheimer's disease model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    100 μg/day · intranasal · 14 consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    However, Pram treatment did not alter the Aβ1-42-induced anhedonic behavior, oxidative stress parameters, or the pre-synaptic SNAP-25 and post-synaptic PSD-95 levels in the hippocampus and prefrontal cortex.
    1 context sentence
    Summary · context
    In this study, we examined the effects of the intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions (PEC-NEDexS/Pram) in an experimental model of AD induced by intracerebroventricular (i.c.v.) infusion of amyloid-beta (Aβ1-<sub…
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice, pramlintide did not alter PSD-95 levels in the hippocampus and prefrontal cortex after amyloid-beta injection.

    In plain wordsIn mice, pramlintide did not change brain PSD-95 levels after amyloid-beta injection.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changePSD-95 levels
    Study

    mousen: not reported in source

    amyloid-beta-induced Alzheimer's disease model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    100 μg/day · intranasal · 14 consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    However, Pram treatment did not alter the Aβ1-42-induced anhedonic behavior, oxidative stress parameters, or the pre-synaptic SNAP-25 and post-synaptic PSD-95 levels in the hippocampus and prefrontal cortex.
    1 context sentence
    Summary · context
    In this study, we examined the effects of the intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions (PEC-NEDexS/Pram) in an experimental model of AD induced by intracerebroventricular (i.c.v.) infusion of amyloid-beta (Aβ1-<sub…

Studies that did not test the peptide alone2

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 08LabNot a test of Pramlintide (Symlin) aloneIn vitro (cell-free)Other

    In formulation tests, dextran-pramlintide nanoemulsions had droplet sizes below 200 nm.

    In plain wordsIn lab tests, dextran-pramlintide nanoemulsion droplets measured below 200 nm.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableDroplet size
    Study

    n: not reported in source

    dextran-pramlintide nanoemulsions
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Measurements

    Droplet size
    < 200 nm
    nanoemulsion

    Source sentences

    Summary
    PEC-NEDexS/Pram displayed droplet size lower than 200 nm and a negatively charged surface.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 09LabNot a test of Pramlintide (Symlin) aloneIn vitro (cell-free)Other

    In formulation tests, dextran-pramlintide nanoemulsions had a negatively charged surface.

    In plain wordsIn lab tests, dextran-pramlintide nanoemulsions had a negative surface charge.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableSurface charge
    Study

    n: not reported in source

    dextran-pramlintide nanoemulsions
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    PEC-NEDexS/Pram displayed droplet size lower than 200 nm and a negatively charged surface.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.